Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update

Simply Wall St.06-05 13:35

Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641197658?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","is_english":true,"pubTime":"2026-06-05 13:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641197658","market":"nz","top_or_hot":-1,"title":"Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update","media":"Simply Wall St.","content":"<div>\n<p>Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-valuation-check-after-cytomx\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-valuation-check-after-cytomx><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-valuation-check-after-cytomx\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089984988.USD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-valuation-check-after-cytomx","article_id":"2641197658","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-valuation-check-after-cytomx","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641197658","pubTimestamp":1780637750,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis, which together have supported fresh interest in the stock.\nSee our latest analysis for Regeneron Pharmaceuticals.\nDespite the positive reaction to the CytomX expansion and Lynozyfic data, Regeneron’s 1-day share price return of 1.58% sits against a year-to-date share price decline of 19.01%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4588":"碎股","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","REGN":"再生元制药公司","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc"},"translate_title":"CytomX合作扩展和Lynozyfic试验更新后再生元制药(REGN)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5},"content_text":"Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis, which together have supported fresh interest in the stock. See our latest analysis for Regeneron Pharmaceuticals. Despite the positive reaction to the CytomX expansion and Lynozyfic data, Regeneron’s 1-day share price return of 1.58% sits against a year-to-date share price decline of 19.01%. The 1-year total shareholder return of 30.87% reflects earlier strength now giving way to softer recent momentum. If you are watching how biotech pipelines can move stocks, it is a good time to widen the search using a screener focused on 40 healthcare AI stocks With Regeneron trading at US$628.73 and an intrinsic value estimate that implies a 71.6% discount, alongside a 32.5% gap to the average analyst target, you have to ask: is this a genuine opportunity, or is the market already baking in future growth? AdvertisementMost Popular Narrative: 28.2% Undervalued Regeneron’s fair value in the most followed narrative sits at $875.31 versus the last close of $628.73, framing a sizeable valuation gap driven by long term pipeline expectations.  Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.  Read the complete narrative. Curious what sits behind that premium to current pricing? The narrative leans on a specific mix of revenue expansion, margin assumptions, and a higher future earnings multiple. The exact blend of growth, profitability, and discount rate inputs might surprise you. If you want to see how those moving parts combine into that $875.31 figure, the full narrative lays it out in detail. Result: Fair Value of $875.31 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upside story still leans heavily on EYLEA in a competitive, pricing sensitive market, and on high R&D spend that may not always translate into commercially successful drugs. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Next Steps With sentiment divided between recent price action and longer term potential, it makes sense to look at the numbers yourself and decide quickly where you stand. To see what investors view as the key upsides before you firm up your own stance, check out the 4 key rewards Looking for more investment ideas? If you stop here, you risk missing other stocks that might fit your style even better, so take a few minutes and broaden your watchlist with focused screeners.  Spot potential value opportunities early by scanning 47 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them yet. Prioritise resilience by reviewing 65 resilient stocks with low risk scores that score well on financial health and lower overall risk profiles. Get ahead of the crowd by searching a screener containing 22 high quality undiscovered gems that are not widely followed but still show solid underlying metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641197658","isCrawlerRequest":true}